title: Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting beta2-agonists.
abstract: OBJECTIVE
  An analysis of 5 double-blinded, randomized, 12-week asthma trials was undertaken to evaluate pediatric subjects (4 to 11 years; n=276) who were previously receiving short-acting beta2-agonists alone and subsequently received treatment with placebo. At baseline, all subjects met National Asthma Education and Prevention Program criteria for moderate/severe asthma.
  
  
  METHODS
  Asthma severity was categorized individually for symptoms, albuterol use, and morning peak expiratory flow and then overall taking into account all three parameters.
  
  
  RESULTS
  Subjects spent the majority of weeks (55%) in the moderate/severe category. Subjects spent approximately 48%, 31%, and 22% of weeks in intermittent, mild, and moderate/severe categories and 57%, 27%, and 15% of weeks, respectively, based on asthma symptoms and albuterol use. Subjects spent approximately 62%, 31%, and 8% of weeks in intermittent/mild, moderate, and severe categories, based on peak expiratory flow; however, >35% of subjects exhibited >or=15 changes in asthma severity classification, based on peak expiratory flow.
  
  
  CONCLUSIONS
  Asthma is a disease with varying symptomatology, and pediatric subjects frequently move between severity categories, especially in children with inadequate asthma control. These data also emphasize that asthma severity cannot be determined in many pediatric subjects by discrete, point-in-time assessments of lung function, albuterol use, or asthma symptoms. Failure to recognize this problem may contribute to underestimation of disease severity in pediatric subjects.
authors.affiliation: Capital Allergy and Respiratory Disease Center, Sacramento, California 95819, and University of Wisconsin, Madison, Wisconsin, USA. bchipps@capitalallergy.com
authors.forename: Bradley E
authors.initials: BE
authors.lastname: Chipps
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Spahn
authors.forename: Christine A
authors.initials: CA
authors.lastname: Sorkness
authors.forename: Leslie
authors.initials: L
authors.lastname: Baitinger
authors.forename: Laura B
authors.initials: LB
authors.lastname: Sutton
authors.forename: Amanda H
authors.initials: AH
authors.lastname: Emmett
authors.forename: Paul M
authors.initials: PM
authors.lastname: Dorinsky
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000420:Albuterol / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D000318:Adrenergic beta-Agonists; D000420:Albuterol